Oncology

Latest News

FDA Approved | Image credit: chrisdorney – stock.adobe.com
Teliso-V Approved to Treat Advanced NSCLC With High c-Met Protein Overexpression

May 14th 2025

Telisotuzumab vedotin (Teliso-V) gained FDA approval as a targeted therapy for patients with advanced non–small cell lung cancer (NSCLC) with high c-Met overexpression, offering new hope.

While CTCs were identified regardless of disease stage, the current study identified large variations in the presence of CTCs between nonmetastatic and metastatic disease | Image Credit: Innovative Creation - stock.adobe.com
Flow Cytometry Can Reliably Identify CTC in Melanoma

May 14th 2025

Jack & Sheryl Morris Cancer Center | Image credit: RWJBarnabas Health
New Jersey’s First Freestanding Cancer Hospital Opens in New Brunswick

May 14th 2025

At 3 months, hospitalizations among patients enrolled in RSM were 19% lower vs historical controls. | Image Credit: Nuttapong punna - stock.adobe.com
Remote Symptom Monitoring Linked to Reduced Hospitalization Risk for Patients With Cancer

May 14th 2025

Offline data augmentation can significantly enhance deep learning techniques, improving classification performance compared to models trained solely on original clinician skin images. | Image Credit: Alexander - stock.adobe.com
Optimized Deep Learning Model Classifies Smartphone Images of Malignant Skin Lesions

May 12th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Site Logo
October 20th 2019

Medical World News

AJMC Staff
Managed care and clinical updates in cancer treatment.
Site Logo
October 20th 2019

Institute for Value-Based Medicine: Philadelphia Region, Fall 2019

Matthew Gavidia Jaime Rosenberg
Speakers from major area cancer centers and Independence Blue Cross addressed progress in implementing value-based care initiatives during a session held September 19, 2019.
Site Logo
October 20th 2019

Conference Coverage: NCCN Policy Summit September 2019

Jaime Rosenberg
Speakers at the September 12, 2019, Policy Summit of the National Comprehensive Cancer Center, held in Washington, DC, addressed what practices have learned from experience with the Oncology Care Model and what steps must occur to standardize patient reported outcomes to incorporate them into reporting.
AJMC® in the Press, October 18, 2019
October 18th 2019

AJMC® in the Press, October 18, 2019

AJMC Staff
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
This Week in Managed Care: October 18, 2019
October 18th 2019

This Week in Managed Care: October 18, 2019

This week, the top managed care news included a new guide that balances curbs on opioid abuse with the needs of patients with chronic pain; HHS proposed reforming antikickback rules to help boost value-based care; a report found flaws with Medicaid work requirements.
Site Logo
October 17th 2019

ASTRO Calls for Voluntary Start, Scaling Back Excessive Cuts in CMS' Proposed Radiation Oncology Model

Paul Harari, MD, FASTRO
In a commentary adapted from the organization's official response to CMS' proposal, the author highlights potential challenges that proposed alternative payment model presents for members of the American Society for Radiation Oncology (ASTRO).
Site Logo
October 17th 2019

Real-World Evidence: Research Reveals a Lack of Racial Diversity in Clinical Trials for Cancer Drugs

Matthew Gavidia
Site Logo
October 17th 2019

Screening and Prevention: More Data Reveal Shift to Obesity-Related Cancers in Younger Patients

Mary Caffrey
Although results of other recent studies have noted the rise in the rate of obesity-related cancers among younger adults, this is the first study to also find a concurrent decrease in the rate of new cancer cases among patients 65 years and older.
Bradley Prechtl Highlights the Importance of Offering Clinical Trials
October 17th 2019

Bradley Prechtl Highlights the Importance of Offering Clinical Trials

Offering clinical trials is paramount, explained Bradley Prechtl, MBA, chief executive officer of Florida Cancer Specialists and the American Oncology Network.
Site Logo
October 17th 2019

How Obesity Affects Cancer Treatment, and How to Talk With Patients About Prevention

An Interview With Debra Patt, MD, MPH, MBA, by Jaime Rosenberg
Debra Patt, MD, MPH, MBA, an oncologist who specializes in breast cancer and who serves as executive vice president at Texas Oncology, discusses the effect of obesity on cancer treatment as well as prevention strategies.
Site Logo
October 16th 2019

Obesity and Cancer Risk: A Public Health Crisis

Alexander J. Alvarnas Joseph C. Alvarnas, MD
Obesity is associated with a number of adverse health-related complications and carries an elevated individual all-cause mortality risk. It would be hard to overstate the increased adverse health outcomes for obese individuals. What is far less well recognized by the general public is the significant link between obesity and increased cancer risk.
Tesh Khullar: How Community Oncologists Can Get Ahead of Changes in Reimbursement for Biosimilars
October 15th 2019

Tesh Khullar: How Community Oncologists Can Get Ahead of Changes in Reimbursement for Biosimilars

Practices are going to have to decide which biosimilar manufacturers they want to be able to partner with, explained Tesh Khullar, senior vice president & advisor, Flatiron Health.
Site Logo
October 15th 2019

NASH and Liver Cancer: The New Cancer Headline

Donna Cryer, JD
The most common primary liver cancer, hepatocellular carcinoma, is driven by fatty liver disease and is among the most prevalent and deadly of cancers driven by obesity. Rising rates of overweight and obesity parallel increased rates of obesogenic cancers, which increased 7% between 2005 and 2014.
MBC Treatment Not Aligned With NCCN Guidelines Leads to Higher Patient Cost Responsibility
October 15th 2019

MBC Treatment Not Aligned With NCCN Guidelines Leads to Higher Patient Cost Responsibility

Allison Inserro
Patients on Medicare with metastatic breast cancer who receive treatment that is discordant with NCCN guidelines bear a greater burden of patient cost responsibility than patients who do receive care according to treatment guidelines.
Erich Mounce: Partnerships and Performance Data Can Initiate Sustainable Growth in Clinical Practice
October 14th 2019

Erich Mounce: Partnerships and Performance Data Can Initiate Sustainable Growth in Clinical Practice

Initiating sustainable growth in clinical practices can be difficult, but through economies of scale derived from partnerships and performance data collection, optimal care can be administered efficiently, said Erich Mounce, chief operating officer, OneOncology.
Dr Amila Patel: How Flatiron's Clinical Workflow Efforts Will Expand Beyond EHRs
October 13th 2019

Dr Amila Patel: How Flatiron's Clinical Workflow Efforts Will Expand Beyond EHRs

Amila Patel, PharmD, BCOP, technical lead, Clinical Oncology, Flatiron Health, discusses how Flatiron is working to implement clinical workflow features that expand beyond the electronic health record (EHR).
Trends in Oncology Dr Michael Kolodziej Expects to See in Coming Years
October 11th 2019

Trends in Oncology Dr Michael Kolodziej Expects to See in Coming Years

Michael Kolodziej, MD, vice president and chief innovation officer at ADVI Health, Inc., outlines the trends he expects to see in the coming years that will impact oncology.
Dr James Hamrick: There's Been Progress in Patient-Centered Care, Albeit Slow
October 8th 2019

Dr James Hamrick: There's Been Progress in Patient-Centered Care, Albeit Slow

The healthcare system has gotten better at placing more of a priority on patient-centered care, but the progress has been slow, said James Hamrick, MD, senior medical director at Flatiron Health.
Nobel Prize Honors 3 Who Showed How Cells Adapt to Oxygen Levels
October 7th 2019

Nobel Prize Honors 3 Who Showed How Cells Adapt to Oxygen Levels

Mary Caffrey
The mechanism studied affects a broad range of physiological responses and is now the focus of intense study by the pharmaceutical industry.
Dr Lawrence Shulman Discusses the Role of Rising Drug Costs in Value-Based Care
October 6th 2019

Dr Lawrence Shulman Discusses the Role of Rising Drug Costs in Value-Based Care

Lawrence N. Shulman, MD, director of the Center for Global Cancer Medicine at the Abramson Cancer Center, and professor of Medicine at the Hospital of the University of Pennsylvania, explains how providers are reacting to more effective, more costly therapies entering the cancer landscape.
Nina Chavez on How CAR T, Other Expensive Therapies Create Reimbursement Challenges
October 5th 2019

Nina Chavez on How CAR T, Other Expensive Therapies Create Reimbursement Challenges

Nina Chavez, MBA, FACMPE, chief operating officer, New Mexico Oncology Hematology Consultants, Ltd., explains how expensive therapies like chimeric antigen receptor (CAR) T-cell therapy are creating reimbursement challenges.
Implementing Practice Transformation, Integrating Primary Care to Provide High-Quality Cancer Care
October 2nd 2019

Implementing Practice Transformation, Integrating Primary Care to Provide High-Quality Cancer Care

Jaime Rosenberg
As practices work to provide the best care for their patients while also containing costs, it has become clear that the old ways of doing things won’t cut it.
Nina Chavez: OCM Has Made Community Oncologists Better Business People
September 30th 2019

Nina Chavez: OCM Has Made Community Oncologists Better Business People

The Oncology Care Model (OCM) over the last couple of years has helped us to look at things that we didn’t really think of from an oncology perspective, explained Nina Chavez, MBA, FACMPE, chief operating officer, New Mexico Oncology Hematology Consultants, Ltd.
Tesh Khullar Discusses the Emerging Role of Biosimilars in Oncology
September 29th 2019

Tesh Khullar Discusses the Emerging Role of Biosimilars in Oncology

Tesh Khullar, senior vice president & advisor, Flatiron Health, discusses the first to anticancer biosimilars having recently entered the market.
Defining, Standardizing, and Acting on Patient-Reported Outcomes in Cancer Care
September 27th 2019

Defining, Standardizing, and Acting on Patient-Reported Outcomes in Cancer Care

Jaime Rosenberg
During a panel discussion on defining, standardizing, and reporting quality in cancer care during the National Comprehensive Cancer Network Policy Summit held September 12 in Washington, DC, it became clear that stakeholders of all backgrounds have set their focus on one type of metric in particular: patient-reported outcomes.
Site Logo
September 27th 2019

Facilitating the Qualitative Improvement of Oncology Through Value-Based Care

Matthew Gavidia
Coverage of the first half of the Institute for Value-Based Medicine® (IVBM®) session held September 19, 2019, in Philadelphia, Pennsylvania. IVBM® is an initiative of The American Journal of Managed Care®.
Dr Blase Polite Outlines the Decision to Move to 2-Sided Risk in the OCM
September 22nd 2019

Dr Blase Polite Outlines the Decision to Move to 2-Sided Risk in the OCM

CMS is trying to make a 2-sided risk model in the Oncology Care Model enticing for practices, but there is still a lot of math practices need to work out before making the decision, said Blase Polite, MD, associate professor of medicine and the executive director for accountable care at the University of Chicago.
Dr James Hamrick Discusses Bringing Value to Patients Through Engagement
September 21st 2019

Dr James Hamrick Discusses Bringing Value to Patients Through Engagement

The more engaged patients who have more access to their data and are more informed about what’s going on are actually going to have better outcomes most of the time, explained James Hamrick, MD, senior medical director at Flatiron Health.
Site Logo
September 20th 2019

Florida Cancer Specialists & Research Institute and Humana Sign Multiyear Agreement

Florida Cancer Specialists & Research Institute and Humana Inc. have signed a new multiyear agreement that provides Humana members with in-network access to FCS’ comprehensive range of oncology services.
Too Much, Too Fast: Providers Need More Time to Operationalize Medicare's New Radiation Oncology Model
September 18th 2019

Too Much, Too Fast: Providers Need More Time to Operationalize Medicare's New Radiation Oncology Model

Jessica Walradt
CMS' new radiation oncology payment model is slated to begin on January 1, 2020, but the significant billing changes that the model requires will require more time.
<1
...
212223242526272829
...
185>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo